Natalia Muñoz Angulo

Dr. Natalia Muñoz Angulo

Universidad El Bosque, Bogotá, Colombia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
Diego Alejandro Cubides-DiazDiego Alejandro Cubides-Diaz
Diego Alejandro Cubides-Diaz
Natalia Muñoz AnguloNatalia Muñoz Angulo
Natalia Muñoz Angulo
DMDaniel Arsanios Martin
Daniel Arsanios Martin
AOAna Ovalle
Ana Ovalle
DPDaniel Ricardo Perdomo-Rodriguez
Daniel Ricardo Perdomo-Rodriguez
MDMaria Paula Del-Portillo
Maria Paula Del-Portillo
Pandoraea pnomenusa is a Gram-negative bacterium of the Pandoraea genus and is mainly associated with the colonization of structurally abnormal airways. During the COVID-19 pandemic, many microorganisms have been associated with coinfection and superinfection in SARS-CoV-2 pneumonia, but so far, no coinfection or superinfection by P. pnomenusa has been reported. We present the first case describing this association in a previously healthy patient. Clinical manifestations, treatment, and outcomes are shown.

2 April 2021 in Universitas Médica
Verified
Journal Article
Open access
PDF file
DMDaniel Arsanios Martin
Daniel Arsanios Martin
Natalia Muñoz AnguloNatalia Muñoz Angulo
Natalia Muñoz Angulo
Antibiotic resistance is a major public health problem worldwide, because it increases morbidity and mortality to a large number of pathologies, being responsible for 700,000 deaths per year. It is estimated that by 2050 it will account for up to 10 million deaths per year, becoming the leading cause of mortality over cardiovascular disease and cancer. This discouraging panorama has prompted the research on new antimicrobials, some of which, such as ceftazidime-avibactam (CAZ-AVI), have already been introduced into clinical practice. CAZ-AVI is a combination of a third generation cephalosporin and a new non-β-lactam β-lactamase inhibitor active against multidrug-resistant gram-negative bacteria (MDR), which, due to its high efficacy and low incidence of adverse effects, has been approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and ventilator-associated pneumonia. A narrative review of the literature was carried out covering the main topics related to this antimicrobial, as well as what has been reported so far in our country. La resistencia antibiótica es un gran problema de salud pública a nivel mundial, debido a que aumenta la morbimortalidad por un gran número de patologías, es el responsable de 700.000 muertes por año, y que se estima que para el año 2050 puede alcanzar cifras de hasta 10 millones de muertes por año, llegando a ser la primera causa de mortalidad por encima de las enfermedades cardiovasculares y el cáncer. Este panorama desalentador ha impulsado la investigación de nuevos antimicrobianos, algunos de los cuales, como ceftazidima-avibactam (CAZ-AVI), ya han sido introducidos en la práctica clínica. CAZ-AVI es una combinación de una cefalosporina de tercera generación y un nuevo inhibidor de β-lactamasa activo contra bacterias gram-negativas multidrogorresistentes (MDR) que, por su gran eficacia y baja incidencia de efectos adversos, ha sido aprobada para el tratamiento de infecciones complicadas del tracto urinario, infecciones intraabdominales complicadas y neumonía asociadas al ventilador. Se realizó una revisión narrativa de la literatura abarcando los principales tópicos relacionados con este antimicrobiano, asi como lo reportado en hasta el momento en nuestro país

1 June 2022 in Piel
Verified
Journal Article
Closed access
FGFabio Ernesto González González
Fabio Ernesto González González
Natalia Muñoz AnguloNatalia Muñoz Angulo
Natalia Muñoz Angulo
CCCarolina Ivette Cortés Correa
Carolina Ivette Cortés Correa
ECElkin Omar Peñaranda Contreras
Elkin Omar Peñaranda Contreras

4 March 2022 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
DMDaniel Arsanios Martin
Daniel Arsanios Martin
Diego Alejandro Cubides-DiazDiego Alejandro Cubides-Diaz
Diego Alejandro Cubides-Diaz
Natalia Muñoz AnguloNatalia Muñoz Angulo
Natalia Muñoz Angulo
MPMaria Perez
Maria Perez
MPMarlyn Zamora Posada
Marlyn Zamora Posada
CVCarlos Mauricio Calderon. Vargas
Carlos Mauricio Calderon. Vargas
Transient CD4 lymphocytopenia is defined as the transitory presence of CD4+ T lymphocyte fewer than 300 cells/mm3 or less than 20% of T cells without HIV infection. It can occur due to multiple causes; however, it is rare for it to occur due to opportunistic infections. Few cases have been described in the literature where antimicrobial treatment normalizes the CD4 count, being more frequent in Mycobacterium tuberculosis infections. To date, this phenomenon has not been described in Cryptococcus neoformans infections. This would be the first reported case according to our knowledge, of a patient who normalizes CD4 count after antifungal treatment, later developing alveolar proteinosis due to M. Tuberculosis.


6 October 2021
Verified
Journal Article
Closed access
LGLina P. González-Cardona
Lina P. González-Cardona
Natalia Muñoz AnguloNatalia Muñoz Angulo
Natalia Muñoz Angulo
MMM. Isabel Moreno-Pedraza
M. Isabel Moreno-Pedraza